FF Pharma Overview
- Founded
- 2012
- Status
- Out of Business
- Latest Deal Type
- Out of Business
FF Pharma General Information
Description
Developer of an anti-CD40 monoclonal antibody therapy intended to offer treatment of chronic inflammatory diseases like primary biliary cirrhosis and Crohn's disease. The company's anti-CD40 monoclonal antibody therapy is a negative allosteric modulator of the CD40 pathway and functions as a reversible switch for B cell activation and inhibits immune responses, enabling doctors to offer treatment for chronic inflammatory and autoimmune diseases.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Primary Office
- Yalelaan 46
- 3584 CM Utrecht
- Netherlands
FF Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Out of Business | 01-Sep-2016 | 00.000 | Completed | Out of Business | ||
| 1. Early Stage VC (Series A) | 23-Jan-2013 | 00.000 | 00.000 | Completed | Startup |
FF Pharma Executive Team (6)
FF Pharma Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bram Vanparys Ph.D | PMV | Supervisory Board Member | 000 0000 |
| Kevin Johnson Ph.D | Index Ventures | Board Member | 000 0000 |
| Stéphane Verdood | Vesalius Biocapital Partners | Supervisory Board Member | 000 0000 |